Mentavi Health announced that its landmark, real-world validation study of the Mentavi Diagnostic Evaluation has been published in the peer-reviewed Journal of Clinical Psychiatry (JCP) , a widely read and respected journal. The open-access article demonstrates that Mentavi’s asynchronous, online evaluation is as accurate as a traditional face-to-face clinical interview in the diagnosis of attention-deficit / hyperactivity disorder (ADHD) in adults and provides the first peer-reviewed evidence base for a fully digital diagnostic pathway for adult ADHD. The article posted on Psychiatrist.com at 8:00 am Central time on September 8, 2025 (see link and DOI below).
“Publication in a top-tier peer-review journal moves this evidence base forward, for our diagnostic evaluation specifically and for telehealth in general,” said Barry K. Herman, MD, MMM, Chief Medical Officer at Mentavi Health and first author of the paper. “The study shows that an online ADHD diagnosis can be accurately assessed asynchronously, closing gaps in care created by specialist shortages and long waitlists.”
Andrew J. Cutler, MD, Chief Medical Officer at the Neuroscience Education Institute, Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University, and study co-author, commented: “As one of the first large peer-reviewed evaluations of a telehealth ADHD tool, this paper will shape guidelines and payer policies worldwide.”
“Publication in JCP sets a new standard for evidence-based digital mental health,” added Keith Brophy, CEO of Mentavi Health. “It validates years of work to build the most rigorous online diagnostic platform and expands our mission to remove barriers of access to accurate mental-health assessments.”
The prospective, real-world observational study compared the Mentavi Diagnostic Evaluation—a self-paced, asynchronous questionnaire interpreted by a doctorate-level psychologist—with a structured face-to-face clinical interview conducted via video. Primary endpoints were sensitivity, specificity, and positive predictive value relative to DSM-5 criteria. The protocol was IRB-approved and powered to detect ≥80 % sensitivity with 95 % confidence.
Established as ADHD Online in 2018, Mentavi Health has evolved to encompass a broader range of mental health services. With the mission to make high-quality ADHD assessments accessible to all, Mentavi has grown to address not only ADHD but also the most common related mental health conditions. The nationwide Mentavi Mental Health Diagnostic Evaluation and various treatment options showcase the company’s commitment to providing comprehensive, accessible, compliant online mental health care. For more information, visit mentavi.com.
Tim Cox, ZingPR for Mentavi Health
tim@zingpr.com
1 Additional statistics, subgroup analyses, and methodological details are available in the open-access article ( Journal of Clinical Psychiatry , on September 8, 2025 (J Clin Psychiatry 2025;86(3):25m15846; doi:10.4088/JCP.25m15846).
Journal of Clinical Psychiatry
Observational study
People
Validity of an Online Assessment of Attention-Deficit/Hyperactivity Disorder Among a Real-World Sample of Adults Seeking Web-Based Mental Health Care
8-Sep-2025
Relevant Financial Relationships: Dr Herman is a full-time employee and shareholder of Mentavi Health and a shareholder of Thynk Inc. In the past 24 months, Dr Faraone received income, potential income, travel expenses continuing education support and/or research support from Aardvark, Aardwolf, ADHD Online, AIMH, Akili, Attentiv, Axsome, Genomind, Ironshore, Johnson & Johnson/Kenvue, Kanjo, KemPharm/Corium, Medice, Noven, Otsuka, Sandoz, Supernus, Sky Therapeutics, and Tris. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. He also receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health, Oxford University Press: Schizophrenia: The Facts and Elsevier: ADHD: Non-Pharmacologic Interventions. He is Program Director of www.ADHDEvidence.org and www.ADHDinAdults.com. Dr Faraone’s research is supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement 965381; NIH/NIMH grants U01AR076092, R01MH116037, 1R01NS128535, R01MH131685, 1R01MH130899, U01MH135970, Massachusetts General, Otsuka, Corium Pharmaceuticals, Supernus Pharmaceuticals, Tris Pharmaceuticals, Oregon Health & Science University. His continuing medical education programs are supported by The Upstate Foundation, Corium Pharmaceuticals, Noven, Tris, Pharmaceuticals, and Supernus Pharmaceuticals. Dr Cutler is a consultant and member of the following advisory boards: AbbVie, Acadia, Actinogen, Alfasigma, Alkermes, Anavex Life Sciences, Arrivo BioVentures, Autobahn Therapeutics, Axsome, Biogen, Biohaven, Boehringer Ingelheim, Brii Biosciences, Bristol Myers Squibb, Cerevel, Cognitive Research Corporation, Corium, Delpor, Evolution Research Group, 4M Therapeutics, Intra-Cellular Therapies, Ironshore Pharmaceuticals, J&J Innovative Medicine, Jazz Pharma, Karuna, Knight Therapeutics, LivoNova, Lundbeck, Luye Pharma, MapLight Therapeutics, MedAvante-ProPhase, Mentavi, Neumora, Neurocrine, Neuroscience Education Institute, NeuroSigma, Noven, Otsuka, PaxMedica, Relmada, Sage Therapeutics, Sirtsei Pharmaceuticals, Supernus, Teva, Thynk, Tris Pharma, Vanda Pharmaceuticals, and VistaGen. He is also a member of the speaker bureaus of AbbVie, Alfasigma, Alkermes, Axsome, Boehringer Ingelheim, Bristol Myers Squibb, Corium, Intra-Cellular Therapies, Ironshore Pharmaceuticals, J&J, Lundbeck, Neurocrine, Noven, Otsuka, Supernus, Teva, Tris Pharma, and Vanda Pharmaceuticals. Dr Cutler holds stock options/equity with 4M Therapeutics and is a member of the Data Safety Monitoring Boards of Alar Pharma, COMPASS Pathways, Freedom Biosciences, and Pain Therapeutics. Dr Newcorn is a consultant/advisory board member for AGB Pharma, Cingulate Therapeutics, Hippo T&C, Lumos, Medice, Mentavi Health, MindTension, Otsuka, Signant Health, and Supernus; received research support from Cingulate, MindTension, and Supernus; received honoraria for disease state lectures from Apsen and Otsuka; and served as a consultant for the US National Football League. Drs LaFrance and Ruetsch are full-time employees of Health Analytics, LLC and were contracted by Mentavi Health for this study. Ms Ripper Lewis is a full-time employee and shareholder of Mentavi Health.